→ The FDA is giving priority review to Merck’s $MRK anti-PD-1 therapy, Keytruda, for a new supplemental biologics license application (sBLA). The application is asking for an OK to use Keytruda as a treatment for cervical cancer patients whose cancer has progressed while on (or after) chemotherapy. The sBLA is based in part on data from the company’s Phase II KEYNOTE-158 trial, according to a Merck statement. The FDA set a PDUFA date of June 28, 2018.
→ AstraZeneca company Pearl Therapeutics has inked a co-development deal with London-based drug developer Avillion to push forward an asthma program called PT027. The investigational therapy is a fixed dose combo of budesonide (an inhaled corticosteroid) and albuterol (a short-acting beta-2 agonist). In a statement, Avillion says it will be responsible for developing PT027 and will finance the program all the way through to regulatory approval. No specific financial terms were disclosed.
→ Austin-based Savara $SVRA has dumped a drug it obtained in its reverse merger with Mast Therapeutics last year. The biotech says that Aironite (sodium nitrite inhalation solution) failed a Phase II study among patients suffering from heart failure with preserved ejection fraction.
With additional reporting by John Carroll.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 25,000+ biopharma pros who read Endpoints News by email every day.Free Subscription